{"prompt": "['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', 'NOTES:', 'a.', 'Typical use failure rates may differ from those when used consistently and correctly. Use should be consistent', 'with local regulations regarding the use of contraceptive methods for participants in clinical studies.', 'b.', 'Hormonal contraception may be susceptible to interaction with the study drug, which may reduce the efficacy of', 'the contraceptive method. In this case two highly effective methods of contraception should be utilized during the', 'treatment period and for at least 60 hours after the last dose of study treatment', 'Pregnancy Testing', 'WOCBP should only be included after a confirmed menstrual period and a negative', 'highly sensitive urine or serum pregnancy test', 'Additional pregnancy testing will be performed at approximately monthly intervals', 'during the study treatment period, after the last dose of study treatment and as', 'required locally.', 'Pregnancy testing will be performed whenever a menstrual cycle is missed or when', 'pregnancy is otherwise suspected', 'Pregnancy testing, with a high sensitivity test will be performed using the test kit', 'provided by the central laboratory and approved by the sponsor and in accordance', 'with instructions provided in the test kit package insert.', 'Collection of Pregnancy Information', 'Male participants with partners who become pregnant', \"Investigator will attempt to collect pregnancy information on any male participant's\", 'female partner of a male study participant who becomes pregnant while participating', 'in this study. This applies only to participants who receive study treatment.', 'After obtaining the necessary signed informed consent from the pregnant female', 'partner directly, the investigator will record pregnancy information on the', \"appropriate form and submit it to GSK within 24 hours of learning of the partner's\", 'pregnancy.', 'Partner will also be followed to determine the outcome of the pregnancy.', 'Information on the status of the mother and child will be forwarded to GSK', 'Generally, follow-up will be no longer than 6 to 8 weeks following the estimated', 'delivery date. Any termination of the pregnancy will be reported regardless of fetal', 'status (presence or absence of anomalies) or indication for procedure.', 'Female Participants who become pregnant', 'Investigator will collect pregnancy information on any female participant, who', 'becomes pregnant while participating in this study.', 'Information will be recorded on the appropriate form and submitted to GSK within', \"24 hours of learning of a participant's pregnancy.\", 'Participant will be followed to determine the outcome of the pregnancy. The', 'investigator will collect follow up information on participant and neonate, which will', '72']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'be forwarded to GSK Generally, follow-up will not be required for longer than 6 to 8', 'weeks beyond the estimated delivery date.', 'Any termination of pregnancy will be reported, regardless of fetal status (presence or', 'absence of anomalies) or indication for procedure.', 'While pregnancy itself is not considered to be an AE or SAE, any pregnancy', 'complication or elective termination of a pregnancy will be reported as an AE or', 'SAE.', 'A spontaneous abortion is always considered to be an SAE and will be reported as', 'such.', 'Any SAE occurring as a result of a post-study pregnancy which is considered', 'reasonably related to the study treatment by the investigator, will be reported to GSK', 'as described in Appendix 4. While the investigator is not obligated to actively seek', 'this information in former study participants, he or she may learn of an SAE through', 'spontaneous reporting.', 'Any female participant who becomes pregnant while participating will discontinue', 'study treatment and be withdrawn from the study.', '73']['2016N293064_00', 'CONFIDENTIAL', '2018N394263_00', '205864', '12.6.', 'Appendix 6: Genetics', 'USE/ANALYSIS OF DNA', \"Genetic variation may impact a participant's response to therapy, susceptibility,\", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a blood sample will be collected for DNA analysis.', 'DNA samples will be used for research related to danirixin or COPD and related', 'diseases. They may also be used to develop tests/assays including diagnostic tests)', 'related danirixin treatment, and COPD (and related diseases). Genetic research may', 'consist of the analysis of one or more candidate genes or the analysis of genetic', 'markers throughout the genome (as appropriate).', 'DNA samples will be analyzed if it is hypothesized that this may help further', 'understand the clinical data.', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to danirixin or study treatments of this class. The results of', 'genetic analyses may be reported in the clinical study report or in a separate study', 'summary.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on danirixin (or study treatments of this', 'class) or COPD (and related diseases) continues but no longer than 15 years or other', 'period as per local requirements.', '74']\n\n###\n\n", "completion": "END"}